Back to Journals » Journal of Blood Medicine » Volume 1

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor

Authors Birkeland K, Parra D, Rosenstein R

Published 1 September 2010 Volume 2010:1 Pages 197—219


Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Kade Birkeland1,2, David Parra1,2, Robert Rosenstein2

1Departments of Medicine and Pharmacy, Veterans Affairs Medical Center, West Palm Beach, FL, USA; 2Department of Medicine, Veterans Affairs Medical Center, West Palm Beach, FL, USA

Abstract: The use of antiplatelet agents, specifically the thienopyridines, has become a standard of care in the approach to the patient presenting with an acute coronary syndrome. These drugs irreversibly inhibit the platelet by permanently binding to the surface P2Y12 receptor and blocking the downstream fibrinogen cross-linking between platelets, which leads to aggregation and thrombus. However, currently available therapeutic choices are limited by potential interaction with other medications, slow hepatic conversion to active metabolite, genetic resistance, and narrow therapeutic safety margin. In order to overcome these disadvantages, there has been an interest in developing alternatives to thienopyridines. Recent investigations have included ticagrelor, a reversible inhibitor of the P2Y12 platelet receptor, which appears to have overcome several drawbacks of the current thienopyridines. Its unique pharmacokinetic and pharmacodynamic profiles result in an inhibition of platelet aggregation that is rapid, high, consistent, and less susceptible to interpatient variability than currently available P2Y12 inhibitors. In addition, ticagrelor offers a potential mortality advantage not apparent with current agents. Although questions regarding the nature, magnitude, and clinical significance of several observed adverse effects (dyspnea and ventricular pauses) remain unanswered, it appears that ticagrelor may represent a significant advancement over currently available oral antiplatelet agents.

Keywords: thienopyridine, clopidogrel, prasugrel, P2Y12, antiplatelet therapy, thrombosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]